Phibro Animal Health Corporation to Participate in Bank of America 2026 Virtual Animal Health Summit
Phibro Animal Health Corporation announced its participation in the Bank of America 2026 Virtual Animal Health Summit. Key executives will address financial analysts and investors on February 26, 2026. A live audio presentation will be available on the company's investor relations website, with a replay archived afterward.
Assessing Phibro Animal Health (PAHC) Valuation After Strong Q2 Results And Higher 2026 Earnings Guidance
Phibro Animal Health (PAHC) recently reported strong Q2 results and updated 2026 earnings guidance, leading to a significant increase in its share price. While one narrative suggests the stock is overvalued at $51.85 compared to a $43 fair value, pointing to non-repeatable growth drivers, a discounted cash flow (DCF) model indicates a deep value with a fair value of $119.16. The article encourages investors to analyze different valuation perspectives and consider additional research through various stock screeners.
Why Phibro Animal Health (PAHC) Is Up 32.2% After Raising FY26 Guidance On Animal Health Strength
Phibro Animal Health (PAHC) recently reported strong second-quarter results, with sales rising to US$373.91 million and net income reaching US$27.46 million. This performance led to a raised fiscal 2026 guidance of US$1.45–1.50 billion in net sales and US$85–95 million in net income, primarily driven by the strength of its Animal Health segment. While the company's shares have surged, the investment narrative includes considerations like acquisition integration, margin pressures, leverage, valuation, and recent insider selling.
Phibro Animal Health Corporation Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Phibro Animal Health Corporation (NASDAQ:PAHC) recently reported strong second-quarter results, with revenues exceeding expectations and statutory profit significantly higher than forecasts. Following these positive results, analysts have raised their earnings per share expectations for 2026 and increased the consensus price target for the stock, signaling a more bullish outlook despite predictions of slower revenue growth compared to the broader industry.
Phibro Animal Health (PAHC) Margin Rebound And EPS Surge Test Cautious Growth Narratives
Phibro Animal Health (PAHC) reported strong Q2 2026 results with significant revenue and EPS growth, challenging previous cautious growth narratives despite lower forecast growth compared to the broader US market. The company saw a rebound in net margin to 6.3% but faces mixed valuation signals and concerns about debt coverage by operating cash flow. Investors are evaluating the recent performance against long-term trends and balance sheet risks.
Phibro Animal Health Corporation Reports Second Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation reported strong second-quarter results for the period ended December 31, 2025, with net sales increasing by 21% to $373.9 million and diluted EPS rising to $0.67. The company's Animal Health segment saw significant growth, partly due to the recent MFA portfolio acquisition. Based on this performance, Phibro has raised its financial guidance for fiscal year 2026, projecting net sales between $1.45 billion and $1.50 billion and Adjusted EBITDA between $245 million and $255 million.
Phibro Animal Health Declares Quarterly Cash Dividend
Phibro Animal Health (PAHC) has declared a quarterly cash dividend of $0.12 per share for both its Class A and Class B common stock. This dividend is payable on March 25, 2026, to shareholders of record as of March 4, 2026, signaling the company's commitment to returning capital and confidence in its financial health. While an analyst maintains a "Sell" rating with a $32.00 price target, TipRanks' AI Analyst, Spark, rates PAHC as "Neutral" due to strong earnings and increased guidance, despite financial risks like high leverage and negative cash flow growth.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. The dividend is payable on March 25, 2026, to stockholders of record as of March 4, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for its Class A and Class B common stock. This dividend is payable on March 25, 2026, to stockholders of record as of March 4, 2026. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
Phibro Animal Health Corporation announced it will release its second-quarter financial results on Wednesday, February 4, 2026, after market close. Management will host a conference call and webcast on Thursday, February 5, 2026, at 9:00 AM ET to discuss these results. Interested parties can access the webcast and presentation slides via the company's investor relations website or by dialing into the conference call.
Lobbying Update: $30,000 of PHIBRO ANIMAL HEALTH CORPORATION lobbying was just disclosed
PHIBRO ANIMAL HEALTH CORPORATION (PAHC) disclosed $30,000 in lobbying expenditures for Q4 2025, primarily focused on advocating for pig disease medicines. The article also details recent insider trading activity, showing significant sales by the CEO, and varying hedge fund sentiment with some funds adding and others decreasing their positions. Analyst ratings are split between "Overweight" and "Underperform," with a median price target of $38.5.
Phibro announces quarterly dividend of $0.12 per share
Phibro Animal Health Corporation announced a quarterly dividend of $0.12 per share for holders of its Class A common stock. This dividend is payable on March 27, 2026, to stockholders of record as of February 27, 2026. This announcement reflects the company's regular distribution policy to its shareholders.
Phibro Animal Health (PAHC) director sells $569k in shares By Investing.com
A director at Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a ten-percent owner, sold shares totaling $569,753 between January 13 and January 15, 2026. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. The company's stock has seen significant growth, returning 95% over the past year, and analysts anticipate further growth in net income.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com
BFI Co., LLC, a significant shareholder in Phibro Animal Health Corp (NASDAQ:PAHC), sold 213 shares of Class A Common Stock for $8,554 on January 9, 2026. This transaction follows a remarkable 102.81% return for PAHC shares over the past year. The sale was executed under a Rule 10b5-1 trading plan, and the company has recently reported strong quarterly results and announced a leadership transition.
Phibro Animal Health (PAHC) director sells $569k in shares
A director of Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a ten-percent owner, sold shares of the company totaling $569,753 between January 13 and January 15, 2026, at prices ranging from $40.0233 to $41.1375. These sales were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, Phibro Animal Health has shown strong performance with a 95% return over the past year and a "GREAT" financial health score, with analysts setting price targets between $32 and $50.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 213 shares for $8,554 on January 9, 2026, through a Rule 10b5-1 trading plan. This transaction occurred amidst a strong performance for PAHC shares, which saw a 102.81% return over the past year, though InvestingPro suggests the stock is currently trading above its Fair Value. The sale highlights insider activity as the company also recently reported strong Q1 fiscal year 2026 results and announced a leadership transition.
Phibro Animal Health (PAHC) director sells $569k in shares By Investing.com
A director of Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a significant owner, sold shares totaling $569,753 between January 13 and January 15, 2026, using a pre-arranged trading plan. Despite these sales, the company stock has seen a 95% return over the past year and analysts expect net income growth. Phibro also reported strong Q1 fiscal year 2026 results and announced a CEO transition for July 2026.
Phibro Animal Health (PAHC) director sells $569k in shares
Phibro Animal Health director Jack Bendheim and BFI Co., LLC, a ten-percent owner, sold shares worth $569,753 between January 13 and January 15, 2026, under a pre-arranged trading plan. The sales occurred at prices ranging from $40.0233 to $41.1375, with the stock currently trading at $40.04 and having a 95% return over the past year. Phibro Animal Health has a "GREAT" financial health score and is expected to grow net income this year, with upcoming earnings on February 11 and a CEO transition in July 2026.
Phibro Animal Health (PAHC) director sells $569k in shares
A director and ten-percent owner of Phibro Animal Health (PAHC), Jack Bendheim and BFI Co., LLC, collectively sold shares worth $569,753 between January 13 and January 15, 2026. These sales were executed under a pre-arranged trading plan, while the company's stock has shown a 95% return over the past year. Phibro Animal Health is expected to report strong earnings and maintain a "GREAT" financial health score according to InvestingPro analysis, despite BofA Securities maintaining an Underperform rating.
Phibro Animal Health (PAHC) director sells $569k in shares
A director at Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a major shareholder, sold a total of $569,753 worth of shares between January 13 and January 15, 2026. These sales were conducted under a pre-arranged trading plan, with share prices ranging from $40.0233 to $41.1375. The company recently reported strong Q1 fiscal year 2026 results, surpassing analyst expectations, and is preparing for a CEO transition in July 2026.
A Look At Phibro Animal Health (PAHC) Valuation After Strong Recent Shareholder Returns
Phibro Animal Health (PAHC) has seen strong shareholder returns and is currently trading at US$39.72. While a narrative fair value suggests it's 7.6% undervalued at around US$43, its P/E ratio of 23.7x is higher than the industry average, implying investors are paying a premium. This article explores the valuation and discusses factors influencing its future growth and potential risks.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 213 shares of Class A Common Stock for $8554 on January 9, 2026, as part of a pre-planned trading strategy. This transaction follows a strong performance for PAHC shares over the past year and occurred while the stock traded above its InvestingPro Fair Value. The article also notes PAHC's recent positive financial results, leadership transition, and an increased price target from BofA Securities despite an "Underperform" rating.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554 By Investing.com
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 213 shares of Class A Common Stock for $8,554. The sale was executed on January 9, 2026, at $40.16 per share, following a significant 102.81% return for PAHC shares over the past year. The company recently reported strong Q1 fiscal year 2026 results and is undergoing a leadership transition.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 213 shares of Class A Common Stock for $8,554 on January 9, 2026. This transaction follows a significant 102.81% return for PAHC shares over the past year and occurred under a Rule 10b5-1 trading plan. Despite the stock trading above its Fair Value according to InvestingPro, the company recently reported strong Q1 fiscal year 2026 results and announced a leadership transition plan.
BFI Co sells Phibro Animal Health (PAHC) shares for $8554
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 213 shares for $8,554. This transaction follows a remarkable 102.81% return for PAHC shares over the past year, though the stock is currently trading above its Fair Value according to InvestingPro. The sale was executed under a Rule 10b5-1 trading plan and aligns with recent positive financial results and a leadership transition within Phibro Animal Health.
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148 By Investing.com
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 328 shares of Class A Common Stock for $13,148 on January 7, 2026, under a Rule 10b5-1 trading plan. The shares were sold at a weighted average price of $40.0877, leaving BFI Co. with 38,872 shares, with voting power exercised by Jack Bendheim. This transaction follows Phibro's strong Q1 fiscal year 2026 results and a raised price target from BofA Securities.
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148 By Investing.com
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 328 shares of Class A Common Stock for a total of $13,148. This transaction occurred on January 7, 2026, at a weighted average price of $40.0877. The sale was executed under a Rule 10b5-1 trading plan, and the company recently reported strong Q1 fiscal year 2026 results and announced a leadership transition for July 2026.
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148 By Investing.com
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 328 shares of Class A Common Stock for $13,148 on January 7, 2026. This transaction was part of a Rule 10b5-1 trading plan. The company recently reported strong Q1 fiscal year 2026 results and announced a future leadership transition.
Investors Still Waiting For A Pull Back In Phibro Animal Health Corporation (NASDAQ:PAHC)
Phibro Animal Health Corporation (NASDAQ:PAHC) currently has a high price-to-earnings (P/E) ratio of 23.6x compared to the broader U.S. market. This high P/E is justified by the company's strong recent earnings growth of 289% in the last year and 46% over three years, with analysts forecasting a 20% EPS growth per year for the next three years, substantially higher than the market average of 12%. Investors are confident in Phibro Animal Health's future prospects, suggesting its share price is unlikely to fall significantly soon.
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 328 shares of Class A Common Stock for $13,148 on January 7, 2026. Despite the sale, Phibro Animal Health shows strong financial health and recently reported impressive Q1 fiscal year 2026 results. The company also announced a leadership transition and received a raised price target from BofA Securities due to strong demand and improved profitability.
BFI Co sells Phibro Animal Health (PAHC) shares worth $13,148
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (PAHC), sold 328 shares of Class A Common Stock for $13,148. This transaction was executed under a Rule 10b5-1 trading plan and occurred amidst strong financial performance from Phibro, including outperforming Q1 FY26 earnings estimates and a raised price target from BofA Securities. The company is also preparing for a leadership transition, with Jack Bendheim moving to Executive Chairman and Daniel Bendheim becoming CEO.
Phibro Animal Health (PAHC) plans CEO handoff to Dani Bendheim in 2026
Phibro Animal Health Corporation announced a leadership transition plan where Jack C. Bendheim will step down as CEO and President on July 1, 2026, to become Executive Chairman. His son, Daniel (Dani) Bendheim, currently Executive Vice President, Corporate Strategy, will assume the roles of CEO and President on the same date. Both executives are expected to enter new or amended employment agreements prior to the transition.
Is Phibro Animal Health Corporation's (NASDAQ:PAHC) 22% ROE Strong Compared To Its Industry?
Phibro Animal Health Corporation (NASDAQ:PAHC) has a Return On Equity (ROE) of 22%, which is comparable to the Pharmaceuticals industry average of 21%. While this ROE is respectable, the company also utilizes a high debt-to-equity ratio of 2.39 to achieve these returns. Investors should consider the role of debt in boosting ROE, as high debt levels increase risk even if they inflate profitability metrics.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation announced its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. This dividend is payable on December 17, 2025, to stockholders of record as of November 26, 2025. Phibro Animal Health is a global animal health and nutrition company.
Phibro Animal Health Corporation to Host Webcast and Conference Call on First Quarter Results
Phibro Animal Health Corporation announced it will host a conference call and webcast on Thursday, November 6, 2025, at 9:00 AM Eastern Time to discuss its first-quarter financial results, which are expected to be released after the market closes on Wednesday, November 5, 2025. Interested parties can access the webcast and presentation slides via the company's investor relations website or by phone. A replay will also be available online afterward.
Phibro Animal Health Declares Quarterly Cash Dividend
Phibro Animal Health (PAHC) announced a quarterly cash dividend of $0.12 per share, payable on December 17, 2025, to shareholders of record by November 26, 2025. This decision underscores the company's dedication to delivering shareholder value and strengthening its market stance. Spark, TipRanks’ AI Analyst, rates PAHC as an Outperform due to strong earnings and positive technical indicators, though it notes concerns regarding high leverage and valuation.
Phibro Animal Health (PAHC) director sells $466k in shares
A director at Phibro Animal Health (PAHC), Jack Bendheim, and BFI Co., LLC, a major shareholder, sold 10,560 shares of Class A Common Stock worth $466,630 between November 17 and November 18, 2025, at prices ranging from $43.8196 to $44.5557. These sales were executed as per a Rule 10b5-1 trading plan and occurred while PAHC stock trades near its 52-week high, having delivered significant year-to-date and past-year returns. The company recently reported strong Q1 fiscal year 2026 results, exceeding analyst expectations for both EPS and revenue.
BFI Co. sells Phibro Animal Health (PAHC) shares worth $1.36 million
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 29,337 shares of Class A Common Stock for approximately $1.36 million between November 12 and November 13, 2025. This transaction followed a conversion of Class B to Class A shares and was executed under a pre-arranged Rule 10b5-1 trading plan. This insider sale comes amidst recent strong financial results for Phibro Animal Health and an increased price target from BofA Securities.
Phibro animal health director sells $765k in shares
Jack Bendheim, a director at Phibro Animal Health Corp (NASDAQ:PAHC), and BFI Co., LLC, a ten percent owner, sold a combined total of 18,899 shares of Class A Common Stock between October 22 and October 24, 2025, for approximately $765,941. This occurred as PAHC stock neared its 52-week high, having gained over 122% in the past six months. The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2025.
Phibro Animal Health Corporation Reports First Quarter Results, Updates Financial Guidance
Phibro Animal Health Corporation announced robust first-quarter results for the period ended September 30, 2025, with net sales increasing 40% to $363.9 million and adjusted diluted EPS doubling to $0.73. The strong performance was primarily driven by its Animal Health segment, which saw a 55% rise in net sales, fueled by demand for MFAs, nutritional specialties, and vaccines. Based on this momentum, the Company has raised its fiscal year 2026 Adjusted EBITDA guidance to $230 million to $240 million, while maintaining its net sales guidance.
Phibro Animal Health (PAHC) director sells $1.88 million in stock
A director and a major shareholder of Phibro Animal Health (NASDAQ:PAHC) sold a combined 32,043 shares totaling $1.88 million. These sales occurred in November 2025 via a Rule 10b5-1 trading plan, even as the stock trades near its 52-week high after an impressive 121% year-to-date return. Despite the insider selling, the company demonstrates strong financial health and positive analyst revisions for net income growth.
Phibro Animal Health Corporation Announces National Launch of Restoris™ Piezoelectric Dental Gel for Dogs
Phibro Animal Health Corporation has launched Restoris™ piezoelectric dental gel, a new product designed to treat periodontal disease in dogs. This innovative gel uses piezoelectric particles to stimulate bone growth and reduce pocket depth, offering a dual mechanism of action to restore oral health. Restoris is now available for pre-order and forms part of Phibro's expanding portfolio in companion animal periodontal health.
BFI Co. sells Phibro Animal Health (PAHC) shares worth $677,198
BFI Co., LLC, a significant owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 16,775 shares of Class A Common Stock for over $677,000 between October 17 and October 20, 2025, operating under a pre-arranged trading plan. These sales occurred while PAHC shares were trading near their 52-week high, having seen a 142% return over the past six months. Despite the sales, BFI Co. also acquired Class A shares through conversion, and other recent news highlights Phibro's strong financial performance and strategic expansion.
Phibro Animal Health (PAHC) director sells $296k in shares
Director Jack Bendheim and BFI Co., LLC, a ten percent owner of Phibro Animal Health (PAHC), sold shares worth approximately $296,778 on November 4th and 5th, 2025. These sales, executed under a Rule 10b5-1 trading plan, occurred while PAHC traded near its 52-week high, having returned 127.92% over six months. The company recently reported strong Q1 fiscal year 2026 earnings, outperforming analyst expectations for EPS and revenue, and received a raised price target from BofA Securities due to increased protein demand and improved profitability in the livestock sector.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on its Class A and Class B common stock. The dividend is payable on December 17, 2025, to stockholders of record as of November 26, 2025. Phibro Animal Health Corporation is a global diversified animal health and nutrition company providing solutions for farm and companion animals.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both its Class A and Class B common stock. This dividend is payable on December 17, 2025, to stockholders of record as of November 26, 2025. Phibro Animal Health Corporation operates as a global diversified animal health and nutrition company.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced that its Board of Directors declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend is payable on December 17, 2025, to stockholders of record as of November 26, 2025. Phibro Animal Health Corporation operates as a global diversified animal health and nutrition company.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share. This dividend applies to both Class A and Class B common stock and is payable on December 17, 2025, to shareholders of record as of November 26, 2025. Phibro Animal Health is a global leader in animal health and nutrition, serving livestock producers, farmers, veterinarians, and consumers.
Phibro Animal Health Corporation Declares Quarterly Dividend
Phibro Animal Health Corporation (Nasdaq: PAHC) announced that its Board of Directors has declared a quarterly cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend is payable on December 17, 2025, to stockholders of record as of November 26, 2025. Phibro Animal Health Corporation is a global diversified animal health and nutrition company.
BFI Co. sells Phibro Animal Health (PAHC) shares worth $437,486
BFI Co., LLC, a ten percent owner of Phibro Animal Health Corp (NASDAQ:PAHC), sold 10,560 shares of Class A Common Stock for $437,486 between October 28 and October 30 via a Rule 10b5-1 trading plan. The transactions occurred as PAHC trades near its 52-week high, with significant stock performance over the past year. Phibro Animal Health recently reported strong Q4 2025 earnings, surpassed revenue expectations, and launched new dental health products for canines.
